RecruitingPhase 3NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Sponsor: Amgen
Baltimore, MD · Oxon Hill, MD · Rockville, MD · +137 more sites